Libivirumab Biosimilar - Research Grade

Human

HBVï؟½

5mg/ml

IgG1 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

Blue ice

Hepatitis B virus (HBV) surface antigen remains a primary target for antiviral and vaccine-related research, supporting both neutralization and detection studies. This human IgG1, kappa antibody is an unconjugated, non-therapeutic analog of libivirumab that binds the HBV antigen for functional work. It is prepared in a low-endotoxin format suitable for in vivo experiments and produced in scalable milligram-to-gram quantities to meet the throughput needs of bulk laboratories. For research use only (RUO), it is appropriate as a positive control and active reagent in viral-neutralization assays, antigen-detection panels, in vitro screening, and preclinical models of HBV infection.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks